Pharmicell Co., Ltd. (KRX:005690)
South Korea · Delayed Price · Currency is KRW 14,310
-20 (-0.14%)
Last updated: Feb 4, 2026, 9:00 AM KST
Pharmicell Revenue
Pharmicell had revenue of 3.65B KRW in the quarter ending June 30, 2014, a decrease of -58.16%. This brings the company's revenue in the last twelve months to 23.94B, down -3.60% year-over-year. In the year 2013, Pharmicell had annual revenue of 33.41B with 200.63% growth.
Revenue (ttm)
23.94B
Revenue Growth
-3.60%
P/S Ratio
35.86
Revenue / Employee
n/a
Employees
n/a
Market Cap
858.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2013 | 33.41B | 22.29B | 200.63% |
| Dec 31, 2012 | 11.11B | 829.38M | 8.07% |
| Dec 31, 2011 | 10.28B | 3.07B | 42.47% |
| Dec 31, 2010 | 7.22B | 28.94M | 0.40% |
| Dec 31, 2009 | 7.19B | -1.14B | -13.68% |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.40T |
| Chabiotech | 1.20T |
| Medy-Tox | 241.80B |
| BINEX | 165.64B |
| MEDIPOST | 73.59B |
| Onconic Therapeutics | 46.65B |
| SillaJen | 7.84B |
| Anterogen.Co.,Ltd. | 7.32B |